Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 56% · prior close shown (market closed)
AMGEN INC shows stable business momentum based on AlphaOS pipeline evidence, with weak management execution.
Why it matters: Revenue +9% YoY in Q2 FY2026.
2 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 2d ago
AMGN's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on AMGN.
Free accounts see more of this; Premium sees all of it.
Reported figures for AMGEN INC — research only, not investment advice.
Updated
What happened recently for AMGEN INC (AMGN) — events, not interpretation.
Research & analysis only — not investment advice.
AMGN's AI investment thesis
Upgrade to Premium for AMGN's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$414.61
Market cap
$224.15B
Profitable
Yes
Revenue $10.05B
Net income
$2.38B
FY Sep 23, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for AMGEN INC — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow AMGEN INC through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.
Structured stock intelligence for companies connected to this research.
Demographic gravity is pulling capital into healthcare whether the market notices or not.
The tools to read, edit, and deliver on the genome are maturing faster than the market prices in.